Author(s): Wajid Ahmad, Rihan Jawed, Irfan Khan, Rizwan Khallel, Danish Hakam

Email(s): wajidahmad806@gmail.com

DOI: 10.52711/2231-5713.2023.00040   

Address: Wajid Ahmad*, Rihan Jawed, Irfan Khan, Rizwan Khallel, Danish Hakam
Department of Pharmaceutics, Institute of Pharmacy, Ankara, Turkey.
*Corresponding Author

Published In:   Volume - 13,      Issue - 3,     Year - 2023


ABSTRACT:
The Poly (ADP-ribose) polymerase (PARP) family has many vital capabilities in cellular processes, together with the law of transcription, apoptosis, and the DNA damage reaction. PARP1 possesses Poly (ADP-ribose) pastime and whilst activated via DNA harm, adds branched PAR chains to facilitate the recruitment of different restore proteins to promote the restore of DNA unmarried-strand breaks. PARP inhibitors (PARP1) had been the first approved cancer drugs that in particular focused the DNA damage response in BRCA1/2 mutated ovarian cancers. Considering the fact that then, there have been sizable advances in our know-how of the mechanisms in the back of sensitization of tumors to PARP inhibitors and enlargement of the use of PARP1 to treat several different most cancers types. right here, we assessment the current advances inside the proposed mechanisms of motion of PARP1, biomarkers of the tumor reaction to PARP1, clinical advances in PARP1 therapy, together with the capacity of mixture treatment plans and mechanisms of tumor resistance.


Cite this article:
Wajid Ahmad, Rihan Jawed, Irfan Khan, Rizwan Khallel, Danish Hakam. A Review on Poly (ADP-ribose) Polymerase (PARP) - An Enzyme that Share the ability to Catalyze the Transfer of ADP-Ribose to Target Proteins. Asian Journal of Pharmacy and Technology. 2023; 13(3):223-8. doi: 10.52711/2231-5713.2023.00040

Cite(Electronic):
Wajid Ahmad, Rihan Jawed, Irfan Khan, Rizwan Khallel, Danish Hakam. A Review on Poly (ADP-ribose) Polymerase (PARP) - An Enzyme that Share the ability to Catalyze the Transfer of ADP-Ribose to Target Proteins. Asian Journal of Pharmacy and Technology. 2023; 13(3):223-8. doi: 10.52711/2231-5713.2023.00040   Available on: https://ajptonline.com/AbstractView.aspx?PID=2023-13-3-13


REFERENCES:
1.    Graziani G, Szabó C. Clinical perspectives of PARP inhibitors. Pharmacological research. 2005 Jul 1; 52(1):109-18.
2.    Malviya V. Design and Characterization of Thermosensitive Mucoadhesive Nasal Gel for Meclizine Hydrochloride. International Journal of Pharmaceutical Sciences and Nanotechnology. 2022 Feb 28; 15(1):5782-93.
3.    Burange PJ, Tawar MG, Bairagi RA, Malviya VR, Sahu VK, Shewatkar SN, Sawarkar RA, Mamurkar RR. Synthesis of silver nanoparticles by using Aloe vera and Thuja orientalis leaves extract and their biological activity: a comprehensive review. Bulletin of the National Research Centre. 2021 Dec; 45(1):1-3.
4.    Lord CJ, Ashworth A. Targeted therapy for cancer using PARP inhibitors. Current opinion in pharmacology. 2008 Aug 1; 8(4):363-9.
5.    Malviya V, Pande S. Development and Evaluation of Fast dissolving Film of Fluoxetine hydrochloride. Research Journal of Pharmacy and Technology. 2021 Oct 31; 14(10):5345-0.
6.    Sonnenblick A, De Azambuja E, Azim HA, Piccart M. An update on PARP inhibitors—moving to the adjuvant setting. Nature reviews Clinical oncology. 2015 Jan; 12(1):27-41.
7.    Murai J, Shar-yin NH, Das BB, Renaud A, Zhang Y, Doroshow JH, Ji J, Takeda S, Pommier Y. Trapping of PARP1 and PARP2 by clinical PARP inhibitors. Cancer research. 2012 Nov 1; 72(21):5588-99.
8.    Curtin NJ. PARP inhibitors for cancer therapy. Expert reviews in molecular medicine. 2005 Mar; 7(4):1-20.
9.    Brown JS, Kaye SB, Yap TA. PARP inhibitors: the race is on. British Journal of Cancer. 2016 Mar; 114(7):713-5.
10.    Anwar M, Aslam HM, Anwar S. PARP inhibitors. Hereditary cancer in clinical practice. 2015 Dec; 13(1):1-4.
11.    Malviya V. Preparation and Evaluation of Emulsomes as a Drug Delivery System for Bifonazole. Indian journal of pharmaceutical education and research. 2021 Jan 1; 55(1):86-94.
12.    D’Andrea AD. Mechanisms of PARP inhibitor sensitivity and resistance. DNA repair. 2018 Nov 1; 71:172-6.
13.    LaFargue CJ, Dal Molin GZ, Sood AK, Coleman RL. Exploring and comparing adverse events between PARP inhibitors. The Lancet Oncology. 2019 Jan 1; 20(1):e15-28.
14.    Bitler BG, Watson ZL, Wheeler LJ, Behbakht K. PARP inhibitors: clinical utility and possibilities of overcoming resistance. Gynecologic oncology. 2017 Dec 1; 147(3):695-704.
15.    Underhill C, Toulmonde M, Bonnefoi H. A review of PARP inhibitors: from bench to bedside. Annals of Oncology. 2011 Feb 1; 22(2):268-79.
16.    Malviya V, Thakur Y, Gudadhe SS, Tawar M. Formulation and evaluation of natural gum based fast dissolving tablet of Meclizine hydrochloride by using 3 factorial design 2. Asian Journal of Pharmacy and Pharmacology. 2020; 6(2):94-100.
17.    Tangutoori S, Baldwin P, Sridhar S. PARP inhibitors: A new era of targeted therapy. Maturitas. 2015 May 1; 81(1):5-9.
18.    Malviya V, Ladhake V, Gajbiye K, Satao J, Tawar M. Design and Characterization of Phase Transition System of Zolmitriptan Hydrochloride for Nasal Drug Delivery System. International Journal of Pharmaceutical Sciences and Nanotechnology. 2020 May 31; 13(3):4942-51.
19.    Drean A, Lord CJ, Ashworth A. PARP inhibitor combination therapy. Critical reviews in oncology/hematology. 2016 Dec 1; 108:73-85.
20.    Kummar S, Chen A, Parchment RE, Kinders RJ, Ji J, Tomaszewski JE, Doroshow JH. Advances in using PARP inhibitors to treat cancer. BMC medicine. 2012 Dec; 10(1):1-5.
21.    Malviya VR, Pande SD, Bobade NN. Preparation and Evaluation of Sustained Release Beads of Zolmitriptan Hydrochloride. Research Journal of Pharmacy and Technology. 2019 Dec 30; 12(12):5972-6.
22.    Yap TA, Plummer R, Azad NS, Helleday T. The DNA damaging revolution: PARP inhibitors and beyond. American Society of Clinical Oncology Educational Book. 2019 May 17; 39:185-95.
23.    Malviya V, Burange P, Thakur Y, Tawar M. Enhancement of Solubility and Dissolution Rate of Atazanavir Sulfate by Nanocrystallization. Indian Journal of Pharmaceutical Education and Research. 2021 Jul 1; 55(3):S672-80.
24.    Diantini A, Ghozali M, Sahidin I. A Review of Current treatment for Triple-Negative Breast Cancer (TNBC). Research Journal of Pharmacy and Technology. 2022 Jan 25; 15(1):409-18.
25.    Benafif S, Hall M. An update on PARP inhibitors for the treatment of cancer. OncoTargets and therapy. 2015; 8:519.
26.    Malviya VR, Pande SD. Road CKN. Preparation ad Evaluation of Zolmitriptan Hydrochloride Lozenge. J Pharma Res. 2019; 8(8):624-9.
27.    Malviya VR, Tawar MG. Preparation and Evaluation of Oral Dispersible Strips of Teneligliptin Hydrobromide for Treatment of Diabetes Mellitus. International Journal of Pharmaceutical Sciences and Nanotechnology. 2020 Jan 31; 13(1):4745-52.
28.    Mirza MR, Coleman RL, González-Martín A, Moore KN, Colombo N, Ray-Coquard I, Pignata S. The forefront of ovarian cancer therapy: update on PARP inhibitors. Annals of Oncology. 2020 Sep 1; 31(9):1148-59.
29.    Malviya V, Manekar S. Design, Development and Evaluation of Aceclofenac and Curcumin Agglomerates by Crystallo Co-Agglomeration Technique. Research Journal of Pharmacy and Technology. 2021 Mar 1; 14(3):1535-41.
30.    Jodh R, Tawar M, Burange P, Malviya V. A Pharmacological Review on Orchid Dactylorhiza hatagirea (D. Doon) Soo. Asian Journal of Pharmacy and Technology. 2022 May 25; 12(2):141-5.
31.    Malviya V, Arya A, Burange P, Gajbhiye K, Rathod G, Tawar M. To Evaluate the Cardioprotective effect of Hydroalcoholic Extract of Matricaria chamomilla Linn in Isoproterenol Induced Myocardial Infarction in Wistar Rats. Research Journal of Pharmacy and Technology. 2022 Sep 1; 15(9):3887-92.
32.    Malviya, Vedanshu, Mukund Tawar, Prashant Burange, and Rahul Jodh. "A Brief Review on Resveratrol." (2022): 157-162.
33.    Ahmad W, Quazi J, Khan R, Ahmad N, Ansari N. A Comprehensive Review on Microspheres. Asian Journal of Pharmacy and Technology. 2022 May 25; 12(2):136-40.
34.    Ahmad W, Jawed R. Development and Validation of Stability Indicating RP-HPLC Method for Estimation of Levamisole HCl in Bulk and Tablet Dosage Form. Research Journal of Pharmaceutical Dosage Forms and Technology. 2022 Apr 1; 14(2):111-6.
35.    Ahmad W, Jawed R. Formulation and Evaluation of Chewable Oral Jelly containing Zolmitriptan hydrochloride. Research Journal of Pharmaceutical Dosage Forms and Technology. 2022 Apr 1; 14(2):139-44.
36.    Jawed R, Ahmad W. Effect of Ultraviolet Radiation on Various Bacterial Species. Asian Journal of Pharmaceutical Research. 2022; 12(1):1-4.
37.    Jawed R, Ahmad W. Formulation and Evaluation of Orodispersible Tablet of Cefixime trihydrate by using Fenugreek Mucilage as a Superdisintegrant. Research Journal of Pharmaceutical Dosage Forms and Technology. 2022; 14(1):23-8.
38.    Malviya V, Tawar M, Burange P, Bairagi R. Preparation and Characterization of Gastroretentive Sustained Release In-situ Gel of Lafutidine. International Journal of Pharmaceutical Sciences and Nanotechnology (IJPSN). 2022 Dec 12; 15(6):6216-28.

Recomonded Articles:

Asian Journal of Pharmacy and Technology (AJPTech.) is an international, peer-reviewed journal, devoted to pharmaceutical sciences...... Read more >>>

RNI: Not Available                     
DOI: 10.5958/2231–5713 


Recent Articles




Tags